Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema

Some insurance companies mandate a form of step therapy, which involves initial use of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and use of a more expensive drug.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-08, Vol.387 (8), p.692-703
Hauptverfasser:	Jhaveri, Chirag D., Glassman, Adam R., Ferris, Frederick L., Liu, Danni, Maguire, Maureen G., Allen, John B., Baker, Carl W., Browning, David, Cunningham, Matthew A., Friedman, Scott M., Jampol, Lee M., Marcus, Dennis M., Martin, Daniel F., Preston, Carin M., Stockdale, Cynthia R., Sun, Jennifer K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acuity Adverse events Bevacizumab Clinical trials Diabetes Diabetes mellitus Diabetic retinopathy Edema Endocrinology Eye FDA approval Monoclonal antibodies Ophthalmology Ophthalmology General Patients Retina Values Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Some insurance companies mandate a form of step therapy, which involves initial use of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and use of a more expensive drug.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2204225